中文

康华生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-21
ItemAmountY/Y
Revenue¥0.17B+25.0%
Gross profit¥0.16B
Operating income¥0.03B
Net income¥0.03B+32.1%
Gross margin91.0%Net margin 15.9%
Revenue Q/Q-46.9%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.02B9.0%
R&D¥0.02B11.9%
SG&A¥0.10B58.3%
Tax & other¥0.00B1.3%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

帝科股份胜蓝股份山水比德捷安高科首都在线中船汉光美瑞新材锦盛新材新强联交大思诺四会富仕申昊科技

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies